Back

VaxThera to exclusively license Syn17D-YF, fully synthetic yellow fever vaccine candidate

Verifying
  • VaxThera agreed to exclusively license Codagenix's Syn17D-YF yellow fever vaccine candidate.
  • VaxThera's Medellín facility has potential capacity exceeding 150 million doses annually.
  • WHO's EYE strategy covers yellow fever epidemic elimination from 2017 through 2026.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
VaxThera to exclusively license Syn17D-YF, fully synthetic yellow fever vaccine candidate - CoinPost Terminal